Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|
Gross Profit | $0.0 | ($247.0K) | ($317.0K) | $20.1M | $30.9M | $231.0K | $28.6M | $24.6M | $25.5M | $60.0M |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Protagonist Therapeutics, Inc.'s last 12-month Gross Profit is $321.3M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Protagonist Therapeutics, Inc.'s Gross Profit growth was N/A. The average annual Gross Profit growth rates for Protagonist Therapeutics, Inc. have been 117.6% over the past three years, N/A over the past five years.